Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Concizumab→

Concizumab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1312299-39-0
Molecular formula
C6460H9964N1716O2014S44
Molecular weight
~145900 g/mol
Drug class
Tissue factor pathway inhibitor (TFPI) monoclonal antibodyprocoagulant biologic
Mechanism of action
Binds TFPI and inhibits its anticoagulant activity, increasing tissue factor-initiated thrombin generation and supporting haemostasis in haemophilia.
Indications / reported uses
  • Routine prophylaxis to prevent or reduce bleeding episodes in eligible adults and adolescents aged 12 years and older with haemophilia A or B with inhibitors under the US ALHEMO indication; not for treatment of acute bleeding episodes

Sources: US DailyMed — ALHEMO (concizumab-mtci) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Concizumab Environmental Risk Assessment (ERA) (the Concizumab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.